RadarScreener › PFSA

PFSA

Profusa, Inc.
PFSA stock: dilution, going concern, delisting risk — what the SEC filings say, updated every weekday morning.
Nasdaq · Surgical & Medical Instruments & Apparatus · EDGAR filings (CIK 1859807) · 32 signals · 4 setups · updated Sep 18, 2026

What the filings say Mixed ◆

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.

Radar 94 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 0.3 mo · strongest signal: Equity line (Sep 16, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

Get tomorrow's read on PFSA — free
One email every weekday morning: what changed across PFSA and ~1,400 other microcaps, every claim linked to the filing.
94Radar · attention score (0–100)
93Dilution pressure · financing + balance sheet
89Listing risk · exchange standards
43Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.95

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language) coexists with live selling machinery (convertible note, equity line, pipe). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Convertible noteEquity lineGoing-concern languagePIPE

Listing cliff Pressure ▼ strength 0.90

Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.

Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Delisting languageGoing-concern languageExchange deficiency noticeNear $5M MVLS floorNegative equityReverse split

Death-spiral watch Pressure ▼ strength 1.00

Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.

Would confirm: Rising share count in 10-Q cover vs prior quarter; repeated 424B3 resales; another reverse split proposal.
Would invalidate: Notes repaid in cash / equity line terminated (8-K 1.02); share count flat quarter over quarter.
Convertible noteDelisting languageEquity lineExchange deficiency noticeReverse split

Activist meets distress Mixed ◆ strength 0.55

An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.

Would confirm: 13D/A with a plan (Item 4), DEFC14A proxy contest, or 8-K 5.02 board seats.
Would invalidate: 13D/A showing the position sold down.
New 13D filerGoing-concern language

Analyst note full note in Pro

Sep 18, 2026 · PFSA · red-team verdict publish with caveats

Profusa discloses three financing deals in one month as cash drops to $375k and Nasdaq compliance clock ticks

Profusa, Inc. (PFSA), a medical-device maker with a $1.3M public float and negative $28.2M equity (as of March 31, 2026), executed three separate equity-line and convertible-note transactions on August 12, September 1, and September 16, 2026. The company received a Nasdaq delisting notice on August 26 (disclosed August 31, 8-K) for failing to file its Form 10-Q on time, coming on top of earlier minimum-value-of-listed-securities deficiencies. A Schedule 13D filed August 19 showed a new activist holder taking a >5% position.

Full note (what we noticed, why it may matter, evidence, what could prove us wrong, red-team caveats) is in the Pro digest →

Pro on PFSA
Alerts
One email the morning PFSA files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for PFSA back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 910 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$375Kcash + short-term investments as of Mar 31, 2026
0.3 moestimated runway (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts])
$-28.2Mstockholders' equity as of Mar 31, 2026
$1.3Mpublic float (10-K cover)
4.7Mshares outstanding as of May 13, 2026 · was 4.4M Apr 14, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 171 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Sep 16, 2026 Equity line “equity line” language in 8-K (EX-10.1) filed 2026-09-16 filing 52
Sep 16, 2026 Convertible note “convertible note” language in 8-K (EX-10.1) filed 2026-09-16 filing 45
Sep 16, 2026 PIPE “pipe” language in 8-K (EX-10.1) filed 2026-09-16 filing 38
Sep 16, 2026 Reverse split “reverse split” language in 8-K (EX-10.1) filed 2026-09-16 filing 34
Sep 16, 2026 Delisting language “delisting notice” language in 8-K (8-K) filed 2026-09-16 filing 32
Sep 16, 2026 New debt obligation 8-K Item 2.03 filed 2026-09-16 (accepted 06:11 ET) filing 27
Sep 15, 2026 Delisting language “delisting notice” language in 8-K (8-K) filed 2026-09-15 filing 32
Sep 4, 2026· Form 4 burst 5 Form 4 filings in 30 days filing 14
Sep 1, 2026 Equity line “equity line” language in 8-K (EX-10.1) filed 2026-09-01 filing 52
Sep 1, 2026 Convertible note “convertible note” language in 8-K (EX-10.1) filed 2026-09-01 filing 45
Sep 1, 2026 PIPE “pipe” language in 8-K (EX-10.1) filed 2026-09-01 filing 38
Sep 1, 2026 Reverse split “reverse split” language in 8-K (EX-10.1) filed 2026-09-01 filing 34
Sep 1, 2026 Delisting language “delisting notice” language in 8-K (8-K) filed 2026-09-01 filing 32
Sep 1, 2026 New debt obligation 8-K Item 2.03 filed 2026-09-01 (accepted 08:15 ET) filing 27
Aug 31, 2026 Exchange deficiency notice 8-K Item 3.01 filed 2026-08-31 (accepted 08:54 ET) filing 48
Aug 31, 2026 Delisting language “delisting notice” language in 8-K (8-K) filed 2026-08-31 filing 46
Aug 31, 2026 Reverse split “reverse split” language in 8-K (EX-99.1) filed 2026-08-31 filing 34
Aug 28, 2026 Reverse split “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-28 filing 29
Aug 21, 2026 Equity line “equity line” language in 8-K (EX-10.2) filed 2026-08-21 filing 52
Aug 21, 2026 Convertible note “convertible note” language in 8-K (8-K) filed 2026-08-21 filing 39
Aug 21, 2026 PIPE “pipe” language in 8-K (EX-10.2) filed 2026-08-21 filing 38
Aug 21, 2026 Unregistered sale 8-K Item 3.02 filed 2026-08-21 (accepted 16:05 ET) filing 35
Aug 21, 2026 Reverse split “reverse split” language in 8-K (EX-10.2) filed 2026-08-21 filing 34
Aug 21, 2026 Delisting language “delisting notice” language in 8-K (8-K) filed 2026-08-21 filing 32
Aug 21, 2026 New debt obligation 8-K Item 2.03 filed 2026-08-21 (accepted 16:05 ET) filing 29
Aug 20, 2026 Reverse split “reverse split” language in 8-K (EX-99.1) filed 2026-08-20 filing 34
Aug 19, 2026 New 13D filer Schedule 13D filed 2026-08-19 filing 45
Aug 19, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-19 filing 43
Mar 31, 2026 Runway < 6 months ~0.3 months runway: liquidity $375,000 as of 2026-03-31, burn $16,248,000/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing 38
Mar 31, 2026 Negative equity Stockholders' equity $-28,198,000 as of 2026-03-31 filing 31
Mar 31, 2026 Near $5M MVLS floor Public float $1,300,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing 31
Mar 31, 2026 Cash < current liabilities Liquidity $375,000 vs current liabilities $29,020,000 filing 22

Other forced raise setups

AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans